Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.
Gilead plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with a single shot every year ...
At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...
El Mundo on MSN12h
Drug that protects against HIV with two 'shots' a year, discovery of the year for 'Science'Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...
Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...
The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.
Pharma company Gilead Sciences has been awarded a massive $31.8 million in damages in connection with a lawsuit claiming ...
In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating yesterday.Pick the best stocks and ...
The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.
California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback